Electric field therapy + chemo shows promise against pancreatic cancer

NCT ID NCT05624918

Recruiting now Disease control Sponsor: Ashish Manne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a wearable device that creates electric fields (TTFields) combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that can be removed by surgery. Participants wear the device at least 18 hours daily and receive chemo for three cycles before surgery, then three more cycles after surgery if the tumor is fully removed. The goal is to see if this combination improves survival and increases the chance of successful surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA RESECTABLE PANCREATIC CANCER

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.